Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes

References

• American Diabetes Association. Standards of care in diabetes—2023 abridged for primary care providers. Clin Diabetes. 2023;41(1):4–31. doi:10.2337/cd23-as01
   Google Scholar
• Witters LA. The blooming of the French lilac. J Clin Invest. 2001;108(8):1105–1107. doi:10.1172/jci14178
   PubMed Web of Science ®Google Scholar
• Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019;8(2):156–164. doi:10.1007/s13679-019-00335-3
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576. doi:10.1007/s00125-017-4318-z
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group. N Engl J Med. 1995;333(9):541–549. doi:10.1056/nejm199508313330902
   PubMed Web of Science ®Google Scholar
• King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643–648. doi:10.1046/j.1365-2125.1999.00092.x
   PubMed Web of Science ®Google Scholar
• Engler C, Leo M, Pfeifer B, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018. BMJ Open Diabetes Res Care. 2020;8(1):e001279.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Glucophage (metformin hydrochloride) Tablets; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf. Accessed January 16, 2023.
   Google Scholar
• Tadesse S. Clinical pharmacokinetics of metformin. In: Juber A, Usama A, Mohammad Irfan K, editors. Metformin. IntechOpen; 2021.
   Google Scholar
• LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021;42(1):77–96. doi:10.1210/endrev/bnaa023
   PubMed Web of Science ®Google Scholar
• Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98. doi:10.2165/11534750-000000000-00000
   PubMed Web of Science ®Google Scholar
• Christensen MMH, Højlund K, Hother-Nielsen O, et al. Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol. 2015;71(6):691–697. doi:10.1007/s00228-015-1853-8
   PubMed Web of Science ®Google Scholar
• Triggle CR, Mohammed I, Bshesh K, et al. Metformin: is it a drug for all reasons and diseases? Metabolism. 2022;133:155223. doi:10.1016/j.metabol.2022.155223
   PubMed Web of Science ®Google Scholar
• Sharma KS HL. Insulin and other antidiabetic drugs. In: Sharma and Sharma’s Principles of Pharmacology. 3rd ed. Paras Medical publisher; 2023.
   Google Scholar
• Electronic Medicines Compendium. Metformin: summaries of product characteristics. European Medicines Agency; 2013. Available from: https://www.medicines.org.uk/emc/product/594/smpc#CONTRAINDICATIONS. Accessed January 16, 2023.
   Google Scholar
• Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World J Diabetes. 2021;12(7):916–931. doi:10.4239/wjd.v12.i7.916
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022. doi:10.2337/dci22-0034
   Web of Science ®Google Scholar
• Logie L, Harthill J, Patel K, et al. Cellular responses to the metal-binding properties of metformin. Diabetes. 2012;61(6):1423–1433. doi:10.2337/db11-0961
   PubMed Web of Science ®Google Scholar
• Shitara Y, Nakamichi N, Norioka M, Shima H, Kato Y, Horie T. Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria. Toxicol Sci. 2013;132(1):32–42. doi:10.1093/toxsci/kfs330
   PubMed Web of Science ®Google Scholar
• Gründemann D, Schömig E. Gene structures of the human non-neuronal monoamine transporters EMT and OCT2. Hum Genet. 2000;106(6):627–635. doi:10.1007/s004390000309
   PubMed Web of Science ®Google Scholar
• Koehler MR, Wissinger B, Gorboulev V, Koepsell H, Schmid M. The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26. Cytogenet Cell Genet. 1997;79(3–4):198–200. doi:10.1159/000134720
   PubMedGoogle Scholar
• Minematsu T, Iwai M, Umehara K, Usui T, Kamimura H. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010;38(1):1–4. doi:10.1124/dmd.109.028142
   PubMed Web of Science ®Google Scholar
• Anne T, Nies HK, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. In: Martin F, Fromm RBK, editors. Handb Exp Pharmacol. Springer; 2011:108–128.
   Google Scholar
• Shirasaka Y, Lee N, Zha W, Wagner D, Wang J. Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. Drug Metab Pharmacokinet. 2016;31(5):385–388. doi:10.1016/j.dmpk.2016.04.005
   PubMed Web of Science ®Google Scholar
• Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49(12):2063–2069. doi:10.2337/diabetes.49.12.2063
   PubMed Web of Science ®Google Scholar
• Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism. 1993;42(9):1217–1222. doi:10.1016/0026-0495(93)90284-u
   PubMed Web of Science ®Google Scholar
• Consoli A, Nurjhan N. Contribution of gluconeogenesis to overall glucose output in diabetic and nondiabetic men. Ann Med. 1990;22(3):191–195. doi:10.3109/07853899009147268
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol. 2011;(201):105–167. doi:10.1007/978-3-642-14541-4_3
   PubMedGoogle Scholar
• Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab. 2003;88(3):1323–1332. doi:10.1210/jc.2002-021394
   PubMed Web of Science ®Google Scholar
• Detaille D, Guigas B, Leverve X, Wiernsperger N, Devos P. Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function. Biochem Pharmacol. 2002;63(7):1259–1272. doi:10.1016/s0006-2952(02)00858-4
   PubMed Web of Science ®Google Scholar
• El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223–228. doi:10.1074/jbc.275.1.223
   PubMed Web of Science ®Google Scholar
• Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494(7436):256–260. doi:10.1038/nature11808
   PubMed Web of Science ®Google Scholar
• Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;3:607–614.
   Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–1174. doi:10.1172/jci13505
   PubMed Web of Science ®Google Scholar
• Larsen S, Rabøl R, Hansen CN, Madsbad S, Helge JW, Dela F. Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration. Diabetologia. 2012;55(2):443–449. doi:10.1007/s00125-011-2340-0
   PubMed Web of Science ®Google Scholar
• LaMoia TE, Butrico GM, Kalpage HA, et al. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. Proc Natl Acad Sci USA. 2022;119(10):e2122287119. doi:10.1073/pnas.2122287119
   PubMed Web of Science ®Google Scholar
• Argaud D, Roth H, Wiernsperger N, Leverve XM. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem. 1993;213(3):1341–1348. doi:10.1111/j.1432-1033.1993.tb17886.x
   PubMedGoogle Scholar
• Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63(18):1879–1894. doi:10.2165/00003495-200363180-00001
   PubMed Web of Science ®Google Scholar
• Miller RA, Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. J Clin Invest. 2010;120(7):2267–2270. doi:10.1172/jci43661
   PubMed Web of Science ®Google Scholar
• Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–156. doi:10.1038/nrendo.2013.256
   PubMed Web of Science ®Google Scholar
• Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem. 2011;286(1):1–11. doi:10.1074/jbc.M110.121806
   PubMed Web of Science ®Google Scholar
• Hardie DG. Metformin—acting through cyclic AMP as well as AMP? Cell Metab. 2013;17(3):313–314. doi:10.1016/j.cmet.2013.02.011
   PubMed Web of Science ®Google Scholar
• Johnson RA, Yeung SM, Stübner D, Bushfield M, Shoshani I. Cation and structural requirements for P site-mediated inhibition of adenylate cyclase. Mol Pharmacol. 1989;35(5):681–688.
   PubMed Web of Science ®Google Scholar
• Koch L. New metformin mechanism elucidated in vitro and in vivo. Nat Rev Endocrinol. 2013;9(3):132. doi:10.1038/nrendo.2013.11
   PubMedGoogle Scholar
• Bergeron R, Russell RR 3rd, Young LH, et al. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol. 1999;276(5):E938–44. doi:10.1152/ajpendo.1999.276.5.E938
   PubMedGoogle Scholar
• Foretz M, Ancellin N, Andreelli F, et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes. 2005;54(5):1331–1339. doi:10.2337/diabetes.54.5.1331
   PubMed Web of Science ®Google Scholar
• Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes. 2000;49(6):896–903. doi:10.2337/diabetes.49.6.896
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642–1646. doi:10.1126/science.1120781
   PubMed Web of Science ®Google Scholar
• Schäfer G. Guanidines and biguanides. Pharmacol Ther. 1980;8(2):275–295. doi:10.1016/0163-7258(80)90049-2
   PubMed Web of Science ®Google Scholar
• Wilcock C, Wyre ND, Bailey CJ. Subcellular distribution of metformin in rat liver. J Pharm Pharmacol. 1991;43(6):442–444. doi:10.1111/j.2042-7158.1991.tb03507.x
   PubMed Web of Science ®Google Scholar
• Meng S, Cao J, He Q, et al. Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex. J Biol Chem. 2015;290(6):3793–3802. doi:10.1074/jbc.M114.604421
   PubMed Web of Science ®Google Scholar
• Ravera S, Cossu V, Tappino B, et al. Concentration-dependent metabolic effects of metformin in healthy and Fanconi anemia lymphoblast cells. J Cell Physiol. 2018;233(2):1736–1751. doi:10.1002/jcp.26085
   PubMed Web of Science ®Google Scholar
• Cao J, Meng S, Chang E, et al. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J Biol Chem. 2014;289(30):20435–20446. doi:10.1074/jbc.M114.567271
   PubMed Web of Science ®Google Scholar
• He L, Wondisford FE. Metformin action: concentrations matter. Cell Metab. 2015;21(2):159–162. doi:10.1016/j.cmet.2015.01.003
   PubMed Web of Science ®Google Scholar
• Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355–2369. doi:10.1172/jci40671
   PubMed Web of Science ®Google Scholar
• Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013;19(12):1649–1654. doi:10.1038/nm.3372
   PubMed Web of Science ®Google Scholar
• Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–546. doi:10.1038/nature13270
   PubMed Web of Science ®Google Scholar
• He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137(4):635–646. doi:10.1016/j.cell.2009.03.016
   PubMed Web of Science ®Google Scholar
• Herzig S, Long F, Jhala US, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;413(6852):179–183. doi:10.1038/35093131
   PubMed Web of Science ®Google Scholar
• Howell JJ, Hellberg K, Turner M, et al. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25(2):463–471. doi:10.1016/j.cmet.2016.12.009
   PubMed Web of Science ®Google Scholar
• Hunter RW, Hughey CC, Lantier L, et al. Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nat Med. 2018;24(9):1395–1406. doi:10.1038/s41591-018-0159-7
   PubMed Web of Science ®Google Scholar
• Lv Z, Guo Y. Metformin and its benefits for various diseases. Front Endocrinol. 2020;11:191. doi:10.3389/fendo.2020.00191
   PubMed Web of Science ®Google Scholar
• Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39(2):198–205. doi:10.2337/dc15-0488
   PubMed Web of Science ®Google Scholar
• Gu S, Shi J, Tang Z, et al. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLoS One. 2015;10(5):e0126704. doi:10.1371/journal.pone.0126704
   PubMed Web of Science ®Google Scholar
• Polianskyte-Prause Z, Tolvanen TA, Lindfors S, et al. Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. FASEB j. 2019;33(2):2858–2869. doi:10.1096/fj.201800529RR
   PubMed Web of Science ®Google Scholar
• Sum CF, Webster JM, Johnson AB, Catalano C, Cooper BG, Taylor R. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med. 1992;9(1):61–65. doi:10.1111/j.1464-5491.1992.tb01716.x
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850–858. doi:10.1038/nm.4345
   PubMed Web of Science ®Google Scholar
• Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;24(12):1919–1929. doi:10.1038/s41591-018-0222-4
   PubMed Web of Science ®Google Scholar
• Lee YJ, Jeschke GR, Roelants FM, Thorner J, Turk BE. Reciprocal phosphorylation of yeast glycerol-3-phosphate dehydrogenases in adaptation to distinct types of stress. Mol Cell Biol. 2012;32(22):4705–4717. doi:10.1128/mcb.00897-12
   PubMed Web of Science ®Google Scholar
• Raber I, McCarthy CP, Vaduganathan M, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393(10186):2155–2167. doi:10.1016/s0140-6736(19)30541-0
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi:10.1056/NEJMoa0806470
   PubMed Web of Science ®Google Scholar
• Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–1311. doi:10.2337/dc12-0719
   PubMed Web of Science ®Google Scholar
• Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616–625. doi:10.1001/archinternmed.2009.20
   PubMedGoogle Scholar
• Zhang K, Yang W, Dai H, Deng Z. Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: results from meta-analysis. Diabetes Res Clin Pract. 2020;160:108001. doi:10.1016/j.diabres.2020.108001
   PubMed Web of Science ®Google Scholar
• Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96. doi:10.1186/s12933-019-0900-7
   PubMedGoogle Scholar
• U.S. National Library of Medicine. MetCool ACS”- metformin “cooling” effect on metformin-naive patients treated with PCI because of acute coronary syndrome; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05305898. Accessed May 5, 2023.
   Google Scholar
• Sena CM, Matafome P, Louro T, Nunes E, Fernandes R, Seiça RM. Metformin restores endothelial function in aorta of diabetic rats. Br J Pharmacol. 2011;163(2):424–437. doi:10.1111/j.1476-5381.2011.01230.x
   PubMed Web of Science ®Google Scholar
• Bacchetti T, Masciangelo S, Armeni T, Bicchiega V, Ferretti G. Glycation of human high density lipoprotein by methylglyoxal: effect on HDL-paraoxonase activity. Metabolism. 2014;63(3):307–311. doi:10.1016/j.metabol.2013.10.013
   PubMed Web of Science ®Google Scholar
• Sena CM, Matafome P, Crisóstomo J, et al. Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacol Res. 2012;65(5):497–506. doi:10.1016/j.phrs.2012.03.004
   PubMed Web of Science ®Google Scholar
• Durrington PN, Mackness B, Mackness MI. Paraoxonase and Atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(4):473–480. doi:10.1161/01.ATV.21.4.473
   PubMed Web of Science ®Google Scholar
• Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL. Front Pharmacol. 2015;6:222. doi:10.3389/fphar.2015.00222
   PubMed Web of Science ®Google Scholar
• Sutkowska E, Fortuna P, Kałuża B, Sutkowska K, Wiśniewski J, Prof AG. Metformin has no impact on nitric oxide production in patients with pre-diabetes. Biomed Pharmacother. 2021;140:111773. doi:10.1016/j.biopha.2021.111773
   PubMed Web of Science ®Google Scholar
• Kato Y, Koide N, Komatsu T, et al. Metformin attenuates production of nitric oxide in response to lipopolysaccharide by inhibiting MyD88-independent pathway. Horm Metab Res. 2010;42(9):632–636. doi:10.1055/s-0030-1255033
   PubMed Web of Science ®Google Scholar
• Salvatore T, Pafundi PC, Galiero R, et al. Can metformin exert as an active drug on endothelial dysfunction in diabetic subjects? Biomedicines. 2020;9(1):3. doi:10.3390/biomedicines9010003
   PubMed Web of Science ®Google Scholar
• Kheniser KG, Kashyap SR, Kasumov T. A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function. Obes Sci Pract. 2019;5(1):36–45. doi:10.1002/osp4.309
   PubMed Web of Science ®Google Scholar
• Machado AP, Pinto RS, Moysés ZP, Nakandakare ER, Quintão EC, Passarelli M. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Int J Biochem Cell Biol. 2006;38(3):392–403. doi:10.1016/j.biocel.2005.09.016
   PubMed Web of Science ®Google Scholar
• Matsuki K, Tamasawa N, Yamashita M, et al. Metformin restores impaired HDL-mediated cholesterol efflux due to glycation. Atherosclerosis. 2009;206(2):434–438. doi:10.1016/j.atherosclerosis.2009.03.003
   PubMed Web of Science ®Google Scholar
• Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic effects of metformin in the failing heart. Int J Mol Sci. 2018;19:1.
   Web of Science ®Google Scholar
• Cittadini A, Napoli R, Monti MG, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes. 2012;61(4):944–953. doi:10.2337/db11-1132
   PubMed Web of Science ®Google Scholar
• Kinsara AJ, Ismail YM. Metformin in heart failure patients. Indian Heart J. 2018;70(1):175–176. doi:10.1016/j.ihj.2017.05.009
   PubMedGoogle Scholar
• Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother. 2007;41(4):642–646. doi:10.1345/aph.1H523
   PubMed Web of Science ®Google Scholar
• Wang XF, Zhang JY, Li L, Zhao XY, Tao HL, Zhang L. Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. Clin Exp Pharmacol Physiol. 2011;38(2):94–101. doi:10.1111/j.1440-1681.2010.05470.x
   PubMed Web of Science ®Google Scholar
• Mohan M, Al-Talabany S, McKinnie A, et al. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J. 2019;40(41):3409–3417. doi:10.1093/eurheartj/ehz203
   PubMed Web of Science ®Google Scholar
• Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007;100(3):328–341. doi:10.1161/01.Res.0000256090.42690.05
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648–657. doi:10.1038/ncb839
   PubMed Web of Science ®Google Scholar
• Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577–590. doi:10.1016/s0092-8674(03)00929-2
   PubMed Web of Science ®Google Scholar
• Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: associations, mechanisms, and implications for medical practice. World J Diabetes. 2014;5(3):372–380. doi:10.4239/wjd.v5.i3.372
   PubMedGoogle Scholar
• Ballotari P, Vicentini M, Manicardi V, et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. BMC Cancer. 2017;17(1):703. doi:10.1186/s12885-017-3696-4
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685. doi:10.2337/dc10-0666
   PubMed Web of Science ®Google Scholar
• Bjornsdottir HH, Rawshani A, Rawshani A, et al. A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. Sci Rep. 2020;10(1):17376. doi:10.1038/s41598-020-73668-y
   PubMed Web of Science ®Google Scholar
• van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2569–2578. doi:10.1158/1055-9965.Epi-09-0372
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809. doi:10.1038/nrc2734
   PubMed Web of Science ®Google Scholar
• Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012;17(6):813–822. doi:10.1634/theoncologist.2011-0462
   PubMed Web of Science ®Google Scholar
• Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013;62(7):922–934. doi:10.1016/j.metabol.2013.01.014
   PubMed Web of Science ®Google Scholar
• Mekuria AN, Ayele Y, Tola A, Mishore KM. Monotherapy with metformin versus sulfonylureas and risk of cancer in type 2 diabetic patients: a systematic review and meta-analysis. J Diabetes Res. 2019;7676909. doi:10.1155/2019/7676909
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu HB, Shi XF, Song Y. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis. PLoS One. 2014;9(6):e99577. doi:10.1371/journal.pone.0099577
   PubMed Web of Science ®Google Scholar
• Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8(6):909–915. doi:10.4161/cc.8.6.7933
   PubMed Web of Science ®Google Scholar
• Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031–2040. doi:10.4161/cc.8.13.8814
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269–10273. doi:10.1158/0008-5472.Can-06-1500
   PubMed Web of Science ®Google Scholar
• Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 2008;15(3):833–839. doi:10.1677/erc-08-0038
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol. 2010;116(1):92–98. doi:10.1016/j.ygyno.2009.09.024
   PubMed Web of Science ®Google Scholar
• Isakovic A, Harhaji L, Stevanovic D, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007;64(10):1290–1302. doi:10.1007/s00018-007-7080-4
   PubMed Web of Science ®Google Scholar
• Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011;15(1):166–178. doi:10.1111/j.1582-4934.2009.00954.x
   PubMed Web of Science ®Google Scholar
• Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol. 2008;14(47):7192–7198. doi:10.3748/wjg.14.7192
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res. 2008;1(5):369–375. doi:10.1158/1940-6207.Capr-08-0081
   PubMed Web of Science ®Google Scholar
• Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008;99(11):2136–2141. doi:10.1111/j.1349-7006.2008.00933.x
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576–3586. doi:10.1038/sj.onc.1211024
   PubMed Web of Science ®Google Scholar
• Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem. 2003;278(41):39422–39427. doi:10.1074/jbc.M305371200
   PubMed Web of Science ®Google Scholar
• Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107(6):873–877. doi:10.1002/ijc.11487
   PubMed Web of Science ®Google Scholar
• Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26(13):1932–1940. doi:10.1038/sj.onc.1209990
   PubMed Web of Science ®Google Scholar
• Jones RA, Campbell CI, Gunther EJ, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene. 2007;26(11):1636–1644. doi:10.1038/sj.onc.1209955
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335–348. doi:10.1038/nrc1362
   PubMed Web of Science ®Google Scholar
• Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98(18):10314–10319. doi:10.1073/pnas.171076798
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278–2287. doi:10.1200/jco.2008.20.0766
   PubMed Web of Science ®Google Scholar
• Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94(2):195–199. doi:10.1038/sj.bjc.6602902
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010;1804(3):433–439. doi:10.1016/j.bbapap.2009.12.001
   PubMed Web of Science ®Google Scholar
• Tao T, Su Q, Xu S, et al. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis. J Cell Physiol. 2019;234(3):3088–3104. doi:10.1002/jcp.27129
   PubMed Web of Science ®Google Scholar
• Algire C, Moiseeva O, Deschênes-Simard X, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res. 2012;5(4):536–543. doi:10.1158/1940-6207.Capr-11-0536
   PubMed Web of Science ®Google Scholar
• Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297–3302. doi:10.1200/jco.2009.19.6410
   PubMed Web of Science ®Google Scholar
• Valencia WM, Palacio A, Tamariz L, Florez H. Metformin and ageing: improving ageing outcomes beyond glycaemic control. Diabetologia. 2017;60(9):1630–1638. doi:10.1007/s00125-017-4349-5
   PubMed Web of Science ®Google Scholar
• Campbell JM, Stephenson MD, de Courten B, Chapman I, Bellman SM, Aromataris E. Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. J Alzheimers Dis. 2018;65(4):1225–1236. doi:10.3233/jad-180263
   PubMed Web of Science ®Google Scholar
• Jiang T, Yu JT, Zhu XC, et al. Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. Br J Pharmacol. 2014;171(13):3146–3157. doi:10.1111/bph.12655
   PubMed Web of Science ®Google Scholar
• Lin Y, Wang K, Ma C, et al. Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism. Front Aging Neurosci. 2018;10:227. doi:10.3389/fnagi.2018.00227
   PubMed Web of Science ®Google Scholar
• Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41(1):61–68. doi:10.3233/jad-131901
   PubMed Web of Science ®Google Scholar
• Palleria C, Leporini C, Maida F, et al. Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes. Front Neuroendocrinol. 2016;42:76–92. doi:10.1016/j.yfrne.2016.07.002
   PubMed Web of Science ®Google Scholar
• Vázquez-Manrique RP, Farina F, Cambon K, et al. AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington’s disease. Hum Mol Genet. 2016;25(6):1043–1058. doi:10.1093/hmg/ddv513
   PubMed Web of Science ®Google Scholar
• Gómez-Benito M, Granado N, García-Sanz P, Michel A, Dumoulin M, Moratalla R. Modeling Parkinson’s disease with the alpha-synuclein protein. Front Pharmacol. 2020;11:356. doi:10.3389/fphar.2020.00356
   PubMed Web of Science ®Google Scholar
• Stefanis L. α-synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(2):a009399. doi:10.1101/cshperspect.a009399
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology. 2007;27(5):494–506. doi:10.1111/j.1440-1789.2007.00803.x
   PubMed Web of Science ®Google Scholar
• Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G. Metformin prevents dopaminergic neuron death in MPTP/P-induced mouse model of parkinson’s disease via autophagy and mitochondrial ROS clearance. Int J Neuropsychopharmacol. 2016;19(9). doi:10.1093/ijnp/pyw047
   Web of Science ®Google Scholar
• Saewanee N, Praputpittaya T, Malaiwong N, Chalorak P, Meemon K. Neuroprotective effect of metformin on dopaminergic neurodegeneration and α-synuclein aggregation in C. elegans model of Parkinson’s disease. Neurosci Res. 2021;162:13–21. doi:10.1016/j.neures.2019.12.017
   PubMed Web of Science ®Google Scholar
• Ozbey G, Nemutlu-Samur D, Parlak H, et al. Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation. Pharmacol Rep. 2020;72(5):1397–1406. doi:10.1007/s43440-020-00095-1
   PubMed Web of Science ®Google Scholar
• Katila N, Bhurtel S, Shadfar S, et al. Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson’s disease. Neuropharmacology. 2017;125:396–407. doi:10.1016/j.neuropharm.2017.08.015
   PubMed Web of Science ®Google Scholar
• Barini E, Antico O, Zhao Y, et al. Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy. Mol Neurodegener. 2016;9(11):16. doi:10.1186/s13024-016-0082-7
   Google Scholar
• DiTacchio KA, Heinemann SF, Dziewczapolski G. Metformin treatment alters memory function in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2015;44(1):43–48. doi:10.3233/jad-141332
   PubMed Web of Science ®Google Scholar
• Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes. 2007;56(7):1817–1824. doi:10.2337/db07-0171
   PubMed Web of Science ®Google Scholar
• Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. Ageing Res Rev. 2017;39:46–58. doi:10.1016/j.arr.2016.10.005
   PubMed Web of Science ®Google Scholar
• Piriz J, Muller A, Trejo JL, Torres-Aleman I. IGF-I and the aging mammalian brain. Exp Gerontol. 2011;46(2–3):96–99. doi:10.1016/j.exger.2010.08.022
   PubMed Web of Science ®Google Scholar
• De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA. 2009;106(6):1971–1976. doi:10.1073/pnas.0809158106
   PubMed Web of Science ®Google Scholar
• Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol. 2006;199(2):265–273. doi:10.1016/j.expneurol.2006.01.018
   PubMed Web of Science ®Google Scholar
• Allard JS, Perez EJ, Fukui K, Carpenter P, Ingram DK, de Cabo R. Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice. Behav Brain Res. 2016;301:1–9. doi:10.1016/j.bbr.2015.12.012
   PubMed Web of Science ®Google Scholar
• Chen F, Dong RR, Zhong KL, et al. Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice. Neuropharmacology. 2016;101:123–136. doi:10.1016/j.neuropharm.2015.07.023
   PubMed Web of Science ®Google Scholar
• Lennox R, Porter DW, Flatt PR, Holscher C, Irwin N, Gault VA. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. Neuropharmacology. 2014;86:22–30. doi:10.1016/j.neuropharm.2014.06.026
   PubMed Web of Science ®Google Scholar
• Pintana H, Apaijai N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 2012;91(11–12):409–414. doi:10.1016/j.lfs.2012.08.017
   PubMed Web of Science ®Google Scholar
• Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav. 2012;101(4):564–574. doi:10.1016/j.pbb.2012.03.002
   PubMed Web of Science ®Google Scholar
• Thangthaeng N, Rutledge M, Wong JM, Vann PH, Forster MJ, Sumien N. Metformin impairs spatial memory and visual acuity in old male mice. Aging Dis. 2017;8(1):17–30. doi:10.14336/ad.2016.1010
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Ogawa M, Honjo J, et al. Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia. Diabetol Int. 2015;6(4):268–274. doi:10.1007/s13340-014-0194-7
   Web of Science ®Google Scholar
• Demaré S, Kothari A, Calcutt NA, Fernyhough P. Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system. Expert Rev Neurother. 2021;21(1):45–63. doi:10.1080/14737175.2021.1847645
   PubMed Web of Science ®Google Scholar
• Hervás D, Fornés-Ferrer V, Gómez-Escribano AP, et al. Metformin intake associates with better cognitive function in patients with Huntington’s disease. PLoS One. 2017;12(6):e0179283. doi:10.1371/journal.pone.0179283
   PubMed Web of Science ®Google Scholar
• Largani SHH, Borhani-Haghighi M, Pasbakhsh P, et al. Oligoprotective effect of metformin through the AMPK-dependent on restoration of mitochondrial hemostasis in the cuprizone-induced multiple sclerosis model. J Mol Histol. 2019;50(3):263–271. doi:10.1007/s10735-019-09824-0
   PubMed Web of Science ®Google Scholar
• Paintlia AS, Paintlia MK, Mohan S, Singh AK, Singh I. AMP-activated protein kinase signaling protects oligodendrocytes that restore central nervous system functions in an experimental autoimmune encephalomyelitis model. Am J Pathol. 2013;183(2):526–541. doi:10.1016/j.ajpath.2013.04.030
   PubMed Web of Science ®Google Scholar
• Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6. doi:10.1186/1758-5996-5-6
   PubMed Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. doi:10.1007/s00125-017-4342-z
   PubMed Web of Science ®Google Scholar
• Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593. doi:10.1007/s00125-017-4336-x
   PubMed Web of Science ®Google Scholar
• Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Fam Med Prim Care. 2022;11(3):927–940. doi:10.4103/jfmpc.jfmpc_644_21
   PubMedGoogle Scholar
• Dutta S, Sharma P, Misra AK. SGLT-2 inhibitors: an evidence-based perspective. In: Frontiers in Clinical Drug Research-Diabetes and Obesity. Bentham Science Publisher; 2020:138–155.
   Google Scholar
• Scheen AJ, Paquot N, Lefebvre PJ, et al. L'étude clinique du mois. “United Kingdom Prospective Diabetes Study”: 10 ans plus tard [United Kingdom Prospective Diabetes Study (UKPDS): 10 years later]. Rev Med Liege. 2008;63(10):624–629.
   PubMedGoogle Scholar
• Wexler D Initial management of hyperglycemia in adults with type 2 diabetes mellitus: India; 2022. Available from: https://www.uptodate.com/contents/initial-management-of-hyperglycemia-in-adults-with-type-2-diabetes-mellitus. Accessed January 15, 2023.
   Google Scholar
• Sutkowska E, Fortuna P, Wisniewski J, et al. Low metformin dose and its therapeutic serum concentration in prediabetes. Sci Rep. 2021;11(1):11684. doi:10.1038/s41598-021-91174-7
   PubMed Web of Science ®Google Scholar
• Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006;86(3):658–663. doi:10.1016/j.fertnstert.2006.02.098
   PubMed Web of Science ®Google Scholar
• Gutzin SJ, Kozer E, Magee LA, Feig DS, Koren G. The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis. Can J Clin Pharmacol. 2003;10(4):179–183.
   PubMedGoogle Scholar
• Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003–2015. doi:10.1056/NEJMoa0707193
   PubMed Web of Science ®Google Scholar
• Nguyen L, Chan SY, Teo AKK. Metformin from mother to unborn child - are there unwarranted effects? EBioMedicine. 2018;35:394–404. doi:10.1016/j.ebiom.2018.08.047
   PubMed Web of Science ®Google Scholar
• Beysel S, Unsal IO, Kizilgul M, Caliskan M, Ucan B, Cakal E. The effects of metformin in type 1 diabetes mellitus. BMC Endocr Disord. 2018;18(1):1. doi:10.1186/s12902-017-0228-9
   PubMedGoogle Scholar
• Livingstone R, Boyle JG, Petrie JR. A new perspective on metformin therapy in type 1 diabetes. Diabetologia. 2017;60(9):1594–1600. doi:10.1007/s00125-017-4364-6
   PubMed Web of Science ®Google Scholar
• Al Khalifah RA, Alnhdi A, Alghar H, Alanazi M, Florez ID. The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: a systematic review and meta-analysis. Pediatr Diabetes. 2017;18(7):664–673. doi:10.1111/pedi.12493
   PubMed Web of Science ®Google Scholar
• Liu C, Wu D, Zheng X, Li P, Li L. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther. 2015;17(2):142–148. doi:10.1089/dia.2014.0190
   PubMed Web of Science ®Google Scholar
• Liu W, Yang XJ. The effect of metformin on adolescents with type 1 diabetes: a systematic review and meta-analysis of randomized controlled trials. Int J Endocrinol. 2016;2016:3854071. doi:10.1155/2016/3854071
   PubMed Web of Science ®Google Scholar
• BMJ Publishing Group Limited. What role for metformin in type 1 diabetes? Drug Ther Bull. 2018;56(7):78–80. doi:10.1136/dtb.2018.7.0645
   PubMedGoogle Scholar
• DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65(2):20–29. doi:10.1016/j.metabol.2015.10.014
   PubMed Web of Science ®Google Scholar
• Heaf J. Metformin in chronic kidney disease: time for a rethink. Perit Dial Int. 2014;34(4):353–357. doi:10.3747/pdi.2013.00344
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ratner RE. Metformin and type 2 diabetes prevention. Diabetes Spectr. 2018;31(4):336–342. doi:10.2337/ds18-0020
   PubMedGoogle Scholar
• Abramowicz M, Zuccotti G, Pflomm JM. Metformin for prediabetes. JAMA. 2017;317(11):1171.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2022 abridged for primary care providers. Clin Diabetes. 2022;40(1):10–38. doi:10.2337/cd22-as01
   PubMedGoogle Scholar
• Moin T. Should adults with prediabetes be prescribed metformin to prevent diabetes mellitus? Yes: high-quality evidence supports metformin use in persons at high risk. Am Fam Physician. 2019;100(3):134–135.
   PubMedGoogle Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. doi:10.1056/NEJMoa012512
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Docherty KF, Køber L, et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care. 2021;44(2):586–594. doi:10.2337/dc20-1675
   PubMed Web of Science ®Google Scholar
• Rossing P, Inzucchi SE, Vart P, et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2022;10(1):24–34. doi:10.1016/s2213-8587(21)00295-3
   PubMed Web of Science ®Google Scholar
• Golay A. Metformin and body weight. Int J Obes. 2008;32(1):61–72. doi:10.1038/sj.ijo.0803695
   PubMed Web of Science ®Google Scholar
• Goel S, Singh R, Singh V, et al. Metformin: activation of 5′ AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action. Front Genet. 2022;13:1022739. doi:10.3389/fgene.2022
   PubMed Web of Science ®Google Scholar
• Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):323–329. doi:10.1097/med.0000000000000095
   PubMedGoogle Scholar
• Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27–31. doi:10.1055/s-0032-1327734
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443. doi:10.1056/NEJMoa066224
   PubMed Web of Science ®Google Scholar
• Pinto LC, Rados DV, Remonti LR, Kramer CK, Leitao CB, Gross JL. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr. 2015;7(Suppl 1):A58. doi:10.1186/1758-5996-7-S1-A58
   PubMed Web of Science ®Google Scholar
• Gao L, Huang H, Zhang L, et al. Comparison of beinaglutide versus metformin for weight loss in overweight and obese non-diabetic patients. Exp Clin Endocrinol Diabetes. 2022;130(6):358–367. doi:10.1055/a-1608-0345
   PubMedGoogle Scholar
• Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care. 2012;35(4):731–737. doi:10.2337/dc11-1299
   PubMed Web of Science ®Google Scholar
• Pu R, Shi D, Gan T, et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. Ther Adv Endocrinol Metab. 2020;11:2042018820926000. doi:10.1177/2042018820926000
   Web of Science ®Google Scholar
• Lyu X, Lyu T, Wang X, et al. The antiobesity effect of GLP-1 receptor agonists alone or in combination with metformin in overweight /obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Int J Endocrinol. 2021;2021:6616693. doi:10.1155/2021/6616693
   PubMed Web of Science ®Google Scholar
• Johnson NP. Metformin use in women with polycystic ovary syndrome. Ann Transl Med. 2014;2(6):56. doi:10.3978/j.issn.2305-5839.2014.04.15
   PubMedGoogle Scholar
• Lashen H. Role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2010;1(3):117–128. doi:10.1177/2042018810380215
   PubMedGoogle Scholar
• Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017;108(3):426–441. doi:10.1016/j.fertnstert.2017.06.026
   PubMed Web of Science ®Google Scholar
• Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;12(12):Cd013505. doi:10.1002/14651858.Cd013505
   PubMedGoogle Scholar
• Sam S, Ehrmann DA. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017;60(9):1656–1661. doi:10.1007/s00125-017-4306-3
   PubMed Web of Science ®Google Scholar
• Lisa M, Chirch PL, Mirza F. Metabolic complications of HIV infection. Case-based review. J Clin Outcomes Manag. 2017;24(12):1.
   Google Scholar
• Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006;43(5):645–653. doi:10.1086/507333
   PubMed Web of Science ®Google Scholar
• Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284(4):472–477. doi:10.1001/jama.284.4.472
   PubMed Web of Science ®Google Scholar
• Kohli R, Shevitz A, Gorbach S, Wanke C. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med. 2007;8(7):420–426. doi:10.1111/j.1468-1293.2007.00488.x
   PubMed Web of Science ®Google Scholar
• Harmooshi NN, Abeshtan A, Zakerkish M, Mirmomeni G, Rahim F. The effect of metformin on body mass index and metabolic parameters in non-diabetic HIV-positive patients: a meta-analysis. J Diabetes Metab Disord. 2021;20(2):1901–1911. doi:10.1007/s40200-021-00869-1
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254–258. doi:10.2337/diacare.29.02.06.dc05-1558
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–1305. doi:10.1136/bmj.38415.708634.F7
   PubMed Web of Science ®Google Scholar
• Shen Z, Wen XF, Lan F, Shen ZZ, Shao ZM. The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res. 2002;8(7):2085–2090.
   PubMed Web of Science ®Google Scholar
• Storozhuk Y, Hopmans SN, Sanli T, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 2013;108(10):2021–2032. doi:10.1038/bjc.2013.187
   PubMed Web of Science ®Google Scholar
• Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30(2):214–226. doi:10.1016/j.molcel.2008.03.003
   PubMed Web of Science ®Google Scholar
• Saini KS, Loi S, de Azambuja E, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013;39(8):935–946. doi:10.1016/j.ctrv.2013.03.009
   PubMed Web of Science ®Google Scholar
• Cejuela M, Martin-Castillo B, Menendez JA, Pernas S. Metformin and breast cancer: where are we now? Int J Mol Sci. 2022;23(5):1.
   Web of Science ®Google Scholar
• Byrne FL, Poon IK, Modesitt SC, et al. Metabolic vulnerabilities in endometrial cancer. Cancer Res. 2014;74(20):5832–5845. doi:10.1158/0008-5472.Can-14-0254
   PubMed Web of Science ®Google Scholar
• Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008;110(2):246–250. doi:10.1016/j.ygyno.2008.04.008
   PubMed Web of Science ®Google Scholar
• Takahashi A, Kimura F, Yamanaka A, et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int. 2014;14:53. doi:10.1186/1475-2867-14-53
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Tamaya T. Telomerase activity in the female reproductive tract and neoplasms. Gynecol Oncol. 1998;68(2):145–149. doi:10.1006/gyno.1997.4921
   PubMed Web of Science ®Google Scholar
• Chae YK, Arya A, Malecek MK, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767–40780. doi:10.18632/oncotarget.8194
   PubMed Web of Science ®Google Scholar
• Coperchini F, Leporati P, Rotondi M, Chiovato L. Expanding the therapeutic spectrum of metformin: from diabetes to cancer. J Endocrinol Invest. 2015;38(10):1047–1055. doi:10.1007/s40618-015-0370-z
   PubMed Web of Science ®Google Scholar
• Febbraro T, Lengyel E, Romero IL. Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol. 2014;135(3):614–621. doi:10.1016/j.ygyno.2014.10.011
   PubMed Web of Science ®Google Scholar
• Gong J, Kelekar G, Shen J, Shen J, Kaur S, Mita M. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. Target Oncol. 2016;11(4):447–467. doi:10.1007/s11523-016-0423-z
   PubMed Web of Science ®Google Scholar
• Imai A, Ichigo S, Matsunami K, Takagi H, Yasuda K. Clinical benefits of metformin in gynecologic oncology. Oncol Lett. 2015;10(2):577–582. doi:10.3892/ol.2015.3262
   PubMed Web of Science ®Google Scholar
• Irie H, Banno K, Yanokura M, et al. Metformin: a candidate for the treatment of gynecological tumors based on drug repositioning. Oncol Lett. 2016;11(2):1287–1293. doi:10.3892/ol.2016.4075
   PubMed Web of Science ®Google Scholar
• Tseng CH. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol. 2015;138(1):147–153. doi:10.1016/j.ygyno.2015.03.059
   PubMed Web of Science ®Google Scholar
• Tang YL, Zhu LY, Li Y, et al. Metformin use is associated with reduced incidence and improved survival of endometrial cancer: a meta-analysis. Biomed Res Int. 2017;2017:5905384. doi:10.1155/2017/5905384
   PubMed Web of Science ®Google Scholar
• Ko EM, Walter P, Jackson A, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 2014;132(2):438–442. doi:10.1016/j.ygyno.2013.11.021
   PubMed Web of Science ®Google Scholar
• Al hilli MM, Bakkum-Gamez JN, Mariani A, et al. The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecol Oncol. 2016;140(2):270–276. doi:10.1016/j.ygyno.2015.11.019
   PubMed Web of Science ®Google Scholar
• Lemańska A, Zaborowski M, Spaczyński M, Nowak-Markwitz E. Do endometrial cancer patients benefit from metformin intake? Ginekol Pol. 2015;86(6):419–423. doi:10.17772/gp/2397
   PubMed Web of Science ®Google Scholar
• Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014;132(1):236–240. doi:10.1016/j.ygyno.2013.10.026
   PubMed Web of Science ®Google Scholar
• Hall C, Stone RL, Gehlot A, Zorn KK, Burnett AF. Use of Metformin in obese women with type I endometrial cancer is associated with a reduced incidence of cancer recurrence. Int J Gynecol Cancer. 2016;26(2):313–317. doi:10.1097/igc.0000000000000603
   PubMed Web of Science ®Google Scholar
• Meireles CG, Pereira SA, Valadares LP, et al. Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol. 2017;147(1):167–180. doi:10.1016/j.ygyno.2017.07.120
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(8):707–710. doi:10.1111/dom.12267
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Kim HG, Hien TT, Han EH, et al. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2011;162(5):1096–1108. doi:10.1111/j.1476-5381.2010.01101.x
   PubMed Web of Science ®Google Scholar
• Barrett D, Brown VI, Grupp SA, Teachey DT. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs. 2012;14(5):299–316. doi:10.2165/11594740-000000000-00000
   PubMed Web of Science ®Google Scholar
• Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;441(7092):475–482. doi:10.1038/nature04703
   PubMed Web of Science ®Google Scholar
• Grimaldi C, Chiarini F, Tabellini G, et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia. 2012;26(1):91–100. doi:10.1038/leu.2011.269
   PubMed Web of Science ®Google Scholar
• Leclerc GM, Leclerc GJ, Kuznetsov JN, DeSalvo J, Barredo JC. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts. PLoS One. 2013;8(8):e74420. doi:10.1371/journal.pone.0074420
   PubMed Web of Science ®Google Scholar
• Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res. 2014;162:65–92. doi:10.1007/978-3-319-07323-1_4
   PubMedGoogle Scholar
• Zhang J, Yu XH, Yan YG, Wang C, Wang WJ. PI3K/Akt signaling in osteosarcoma. Clin Chim Acta. 2015;444:182–192. doi:10.1016/j.cca.2014.12.041
   PubMed Web of Science ®Google Scholar
• Mimeault M, Batra SK. Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol. 2007;18(10):1605–1619. doi:10.1093/annonc/mdm070
   PubMed Web of Science ®Google Scholar
• Gao F, Huang W, Zhang Y, et al. Hes1 promotes cell proliferation and migration by activating Bmi-1 and PTEN/Akt/GSK3β pathway in human colon cancer. Oncotarget. 2015;6(36):38667–38680. doi:10.18632/oncotarget.5484
   PubMedGoogle Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• He Z, Liang J, Wang B. Inhibin, beta A regulates the transforming growth factor-beta pathway to promote malignant biological behaviour in colorectal cancer. Cell Biochem Funct. 2021;39(2):258–266. doi:10.1002/cbf.3573
   PubMed Web of Science ®Google Scholar
• Carlton AL, Illendula A, Gao Y, et al. Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition. Gynecol Oncol. 2018;149(2):350–360. doi:10.1016/j.ygyno.2018.03.005
   PubMed Web of Science ®Google Scholar
• Wang Q, Wen YG, Li DP, et al. Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 2012;29(1):77–83. doi:10.1007/s12032-010-9766-y
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhang M, Luo Z, Wen Z, Yan X. The dichotomous role of TGF-β in controlling liver cancer cell survival and proliferation. J Genet Genomics. 2020;47(9):497–512. doi:10.1016/j.jgg.2020.09.005
   PubMed Web of Science ®Google Scholar
• Deng M, Lei S, Huang D, et al. Suppressive effects of metformin on colorectal adenoma incidence and malignant progression. Pathol Res Pract. 2020;216(2):152775. doi:10.1016/j.prp.2019.152775
   PubMed Web of Science ®Google Scholar
• Hou YC, Hu Q, Huang J, Fang JY, Xiong H. Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: a meta-analysis. Oncotarget. 2017;8(5):8843–8853. doi:10.18632/oncotarget.13633
   PubMedGoogle Scholar
• Ala M. The emerging role of metformin in the prevention and treatment of colorectal cancer: a game changer for the management of colorectal cancer. Curr Diabetes Rev. 2022;18(8):e051121197762. doi:10.2174/1573399818666211105125129
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.309
   PubMed Web of Science ®Google Scholar
• Petti C, Vegetti C, Molla A, et al. AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. Melanoma Res. 2012;22(5):341–350. doi:10.1097/CMR.0b013e3283544929
   PubMed Web of Science ®Google Scholar
• Tomic T, Botton T, Cerezo M, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2011;2(9):e199. doi:10.1038/cddis.2011.86
   PubMedGoogle Scholar
• Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, et al. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol. 2011;668(3):373–382. doi:10.1016/j.ejphar.2011.07.004
   PubMed Web of Science ®Google Scholar
• Cerezo M, Tichet M, Abbe P, et al. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther. 2013;12(8):1605–1615. doi:10.1158/1535-7163.Mct-12-1226-t
   PubMed Web of Science ®Google Scholar
• Niehr F, von Euw E, Attar N, et al. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011;9:76. doi:10.1186/1479-5876-9-76
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA. 2013;110(3):972–977. doi:10.1073/pnas.1221055110
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301(6):H2181–90. doi:10.1152/ajpheart.00554.2011
   PubMed Web of Science ®Google Scholar
• Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55(2):496–505. doi:10.2337/diabetes.55.02.06.db05-1064
   PubMed Web of Science ®Google Scholar
• Loi H, Boal F, Tronchere H, et al. Metformin protects the heart against hypertrophic and apoptotic remodeling after myocardial infarction. Front Pharmacol. 2019;10:154. doi:10.3389/fphar.2019.00154
   PubMed Web of Science ®Google Scholar
• Hannenhalli S, Kaestner KH. The evolution of Fox genes and their role in development and disease. Nat Rev Genet. 2009;10(4):233–240. doi:10.1038/nrg2523
   PubMed Web of Science ®Google Scholar
• Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117(4):421–426. doi:10.1016/s0092-8674(04)00452-0
   PubMed Web of Science ®Google Scholar
• Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007;120(Pt 15):2479–2487. doi:10.1242/jcs.001222
   PubMed Web of Science ®Google Scholar
• Dei Cas A, Spigoni V, Ridolfi V, Metra M. Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach. Endocr Metab Immune Disord Drug Targets. 2013;13(1):38–50. doi:10.2174/1871530311313010006
   PubMed Web of Science ®Google Scholar
• Yang X, Xu Z, Zhang C, Cai Z, Zhang J. Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):1984–1990. doi:10.1016/j.bbadis.2016.09.019
   PubMed Web of Science ®Google Scholar
• Hernández JS, Barreto-Torres G, Kuznetsov AV, Khuchua Z, Javadov S. Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria. J Cell Mol Med. 2014;18(4):709–720. doi:10.1111/jcmm.12220
   PubMed Web of Science ®Google Scholar
• Yanazume T, Morimoto T, Wada H, Kawamura T, Hasegawa K. Biological role of p300 in cardiac myocytes. Mol Cell Biochem. 2003;248(1–2):115–119. doi:10.1023/a:1024132217870
   PubMed Web of Science ®Google Scholar
• Bertrand L, Ginion A, Beauloye C, et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol. 2006;291(1):H239–50. doi:10.1152/ajpheart.01269.2005
   PubMed Web of Science ®Google Scholar
• Anisimov VN. Metformin for aging and cancer prevention. Aging. 2010;2(11):760–774. doi:10.18632/aging.100230
   PubMedGoogle Scholar
• Spindler SR. Caloric restriction: from soup to nuts. Ageing Res Rev. 2010;9(3):324–353. doi:10.1016/j.arr.2009.10.003
   PubMed Web of Science ®Google Scholar
• Lund J, Tedesco P, Duke K, Wang J, Kim SK, Johnson TE. Transcriptional profile of aging in C. elegans. Curr Biol. 2002;12(18):1566–1573. doi:10.1016/s0960-9822(02)01146-6
   PubMed Web of Science ®Google Scholar
• Longo VD, Finch CE. Evolutionary medicine: from dwarf model systems to healthy centenarians? Science. 2003;299(5611):1342–1346. doi:10.1126/science.1077991
   PubMed Web of Science ®Google Scholar
• Andújar-Plata P, Pi-Sunyer X, Laferrère B. Metformin effects revisited. Diabetes Res Clin Pract. 2012;95(1):1–9. doi:10.1016/j.diabres.2011.09.022
   PubMed Web of Science ®Google Scholar
• Verdaguer E, Junyent F, Folch J, et al. Aging biology: a new frontier for drug discovery. Expert Opin Drug Discov. 2012;7(3):217–229. doi:10.1517/17460441.2012.660144
   PubMed Web of Science ®Google Scholar
• Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26(3):611–617. doi:10.1161/01.Atv.0000201938.78044.75
   PubMed Web of Science ®Google Scholar
• Glossmann Hartmut H, Lutz Oliver MD. Metformin and Aging: a Review. Gerontology. 2019;65(6):581–590.
   PubMed Web of Science ®Google Scholar
• Mohammed I, Hollenberg MD, Ding H, Triggle CR. A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. Front Endocrinol. 2021;12:718942. doi:10.3389/fendo.2021.718942
   PubMed Web of Science ®Google Scholar
• Walton RG, Dungan CM, Long DE, et al. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: a randomized, double-blind, placebo-controlled, multicenter trial: the MASTERS trial. Aging Cell. 2019;18(6):e13039. doi:10.1111/acel.13039
   PubMed Web of Science ®Google Scholar
• Wensink MJ, Lu Y, Tian L, et al. Preconception antidiabetic drugs in men and birth defects in offspring.: a nationwide cohort study. Ann Intern Med. 2022;175(5):665–673. doi:10.7326/M21-4389
   PubMed Web of Science ®Google Scholar
• Niemuth NJ, Jordan R, Crago J, Blanksma C, Johnson R, Klaper RD. Metformin exposure at environmentally relevant concentrations causes potential endocrine disruption in adult male fish. Environ Toxicol Chem. 2015;34(2):291–296. doi:10.1002/etc.2793
   PubMed Web of Science ®Google Scholar
• Niemuth NJ, Klaper RD. Emerging wastewater contaminant metformin causes intersex and reduced fecundity in fish. Chemosphere. 2015;135:38–45. doi:10.1016/j.chemosphere.2015.03.060
   PubMed Web of Science ®Google Scholar
• Niemuth NJ, Klaper RD. Low-dose metformin exposure causes changes in expression of endocrine disruption-associated genes. Aquat Toxicol. 2018;195:33–40. doi:10.1016/j.aquatox.2017.12.003
   PubMed Web of Science ®Google Scholar
• Madiraju AK, Qiu Y, Perry RJ, et al. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med. 2018;24(9):1384–1394. doi:10.1038/s41591-018-0125-4
   PubMed Web of Science ®Google Scholar